Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | |
| Cash Flows From Operating Activities | ||||
| Depreciation Amortization | 40 | 38 | 20 | 0 |
| Accounts receivable | 60 | -97 | -26 | 0 |
| Accounts payable and accrued liabilities | -165 | 243 | 273 | 9 |
| Other Working Capital | 1,408 | 207 | 304 | 12 |
| Other Operating Activity | -7,649 | -8,485 | -1,611 | -20 |
| Operating Cash Flow | $-6,307 | $-8,094 | $-1,040 | $0 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -3 | N/A | N/A | N/A |
| Purchase Sale Intangibles | N/A | 0 | -127 | 0 |
| Investing Cash Flow | $-3 | $0 | $-127 | $0 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 8,709 | 10,740 | 3,591 | 0 |
| Other Financing Activity | -859 | -901 | 0 | 0 |
| Financing Cash Flow | $7,849 | $9,839 | $3,591 | $0 |
| Exchange Rate Effect | -47 | -113 | 50 | 0 |
| Beginning Cash Position | 4,106 | 2,474 | 0 | 0 |
| End Cash Position | 5,599 | 4,106 | 2,474 | 0 |
| Net Cash Flow | $1,539 | $1,745 | $2,425 | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -6,307 | -8,094 | -1,040 | 0 |
| Capital Expenditure | -3 | N/A | -127 | N/A |
| Free Cash Flow | -6,310 | -8,094 | -1,167 | 0 |